To further confirm the essential role of CD39 in NSCLC-promoted T cell mal-differentiation, we obtained CD39 knockout NSCLC cells by CRISPR/Cas9 technology (Fig. S8B). This evidence concerns the gene ENTPD1 and non-small cell lung carcinoma.